Aktis Oncology, Inc.
Financials
Valuation Metrics
Aktis Oncology, Inc.'s Market Cap is $1.21B. Ranked #2334 of 3,121 in US market (top 75%), #940 of 1,463 on NASDAQ (top 64%), #176 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.21B | US#2,334/3,121 Sec#176/266 |
| Total Assets | $558M | US#2,731/3,121 Sec#153/266 |
| Net Assets | $485M | US#2,253/3,121 Sec#111/266 |
| Employees | 79 | US#2,666/3,121 Sec#193/266 |
| Value | ||
| P/B | 2.49x | US#1,591/3,121 Sec#75/266 |
| P/S | 186.16x | US#2,961/3,121 Sec#187/266 |
| Profitability | ||
| Revenue Growth | 336.92% | US#40/3,121 Sec#17/266 |
| Financial Health | ||
| Debt Ratio | 15.01% | US#176/3,121 Sec#70/266 |
| Total Debt | $11M | US#2,827/3,121 Sec#198/266 |
| Cash | $82M | US#2,338/3,121 Sec#189/266 |
| Current Ratio | 16.33x | US#150/3,121 Sec#42/266 |
| Performance | ||
| 1M Return | -12.55% | US#2,283/3,121 Sec#171/266 |
| From 52W High | -36.00% | US#2,215/3,121 Sec#174/266 |
| 1Y MDD | -32.19% | US#1,571/3,121 Sec#103/266 |
| Trading | ||
| Volume | 2,241,396 shares | US#2,037/3,121 Sec#214/266 |
| Trading Value | $50M | US#2,276/3,121 Sec#187/266 |
| Per Share | ||
| BPS | $8.77 | US#1,930/3,121 Sec#78/266 |
Company Info
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.